[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342107-105":59,"doc-detail-342107-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","respiratory-gated-proton-beam-therapy-for-intrahepatic-cholangiocarcinoma-without-fiducial-markers","Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers","","Intrahepatic cholangiocarcinoma is a difficult primary liver cancer with poor prognosis, particularly when unresectable. Traditional palliative irradiation has limited ability to reduce liver dose. This study assessed efficacy and toxicity of respiratory-gated proton beam therapy delivered without fiducial markers for ICC. Twenty-four patients treated between 2011 and 2022 received 48–83.6 relative biological effectiveness in 20–38 fractions with 4D-CT planning; median follow-up was 18.5 months. Median survival was 28 months, 2-year overall survival 51%, progression-free survival 26%, and local control 73%, with manageable adverse effects.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/respiratory-gated-proton-beam-therapy-for-intrahepatic-cholangiocarcinoma-without-fiducial-markers/342107/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/respiratory-gated-proton-beam-therapy-for-intrahepatic-cholangiocarcinoma-without-fiducial-markers/342107.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of this study?","Question",{"text":112,"@type":113},"To evaluate the efficacy and toxicity of respiratory-gated proton beam therapy without fiducial markers for intrahepatic cholangiocarcinoma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the treatment planned and delivered?",{"text":117,"@type":113},"Patients underwent respiratory-gated proton beam therapy using 4D-CT planning, with 20–38 fractions and a prescribed dose of 48–83.6 relative biological effectiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes were reported for survival and local control?",{"text":121,"@type":113},"The median survival time was 28 months, with 2-year overall survival 51%, progression-free survival 26%, and local tumor control 73%.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342107,1790145992,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Okubo et al. Radiation Oncology (2024) 19:160 [https://doi.org/10.1186/s13014-024-02550-2](https://doi.org/10.1186/s13014-024-02550-2)  \nRadiation Oncology  \n RESEARCH Open Access  \nRespiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers  \nAkihito Okubo1*, Sae Matsumoto2, Hiroyasu Tamamura2, Yoshitaka Sato2, Satoko Asahi2, Hitoshi Tatebe2, Kazutaka Yamamoto2, Keiichiro Matsushita2, Makoto Sasaki2, Yoshikazu Maeda2, Yuji Tameshige2, Hajime Sunagozaka3, Hiroyuki Aoyagi3, Satoshi Shibata1,4, Shigeyuki Takamatsu1 and Satoshi Kobayashi 1  \nAbstract  \nBackground Intrahepatic cholangiocarcinoma (ICC) is a challenging primary liver cancer with a poor prognosis, especially in unresectable cases. Traditional palliative irradiation is limited in reducing liver doses. This study aimed to evaluate the efficacy and toxicity of respiratory-gated proton beam therapy without fiducial markers for intrahepatic cholangiocarcinoma.  \nMethods Between October 2011 and February 2022, 24 patients (median [range] age, 71 [41–88] years) were evaluated at our institution. Twelve patients were pathologically diagnosed with ICC. All patients underwent respiratory-gated proton beam therapy at a dose of 48–83 .6 (relative biological effectiveness) in 20–38 fractions with four-dimensional computed tomography planning. The median follow-up period was 18.5 (range, 2 .0–74. 0) months. The median tumor size was 41 (range, 10–134) mm. Twenty-one patients were classified as having Child– Pugh class A, and three patients were classified as having Child–Pugh class B. Local progression was defined as any growth of the irradiated tumor.  \nResults The median survival time was 28 months for all patients. The Kaplan–Meier estimates of the 2-year overall survival, progression-free survival, and local tumor control rates were 51%, 26%, and 73%, respectively. Local tumor control rates were non-inferior to those reported in previous studies using fiducial markers. One patient had grade 4 pleural effusion; however, whether this was an adverse event due to the proton beam therapy was unclear. Conclusions Respiratory-gated proton beam therapy without fiducial markers is an effective and less invasive treatment option for ICC, showing potential for improved local control and tolerable adverse effects.  \nKeywords Proton beam therapy, Cholangiocarcinoma, 4D-CT, Respiratory-gated irradiation  \nPresentation at a Conference: Sae Matsumoto et al.: Respiratory-gated Proton Beam Therapy for Intrahepatic Cholangiocellular Carcinoma Without Fiducial Markers. ASTRO 2020 Annual Meeting.  \n*Correspondence: Akihito Okubo [aki3720720@yahoo.co.jp](aki3720720@yahoo.co.jp)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nBackground  \nIntrahepatic cholangiocarcinoma (ICC) accounts for 10–20% of pri","cbCaiipXeZRDYz6H","https://ap.wps.com/l/cbCaiipXeZRDYz6H","pdf",1004979,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background\n## Clinical context and challenges\n## Rationale for proton therapy and gating","[{\"question\":\"What was the purpose of this study?\",\"answer\":\"To evaluate the efficacy and toxicity of respiratory-gated proton beam therapy without fiducial markers for intrahepatic cholangiocarcinoma.\"},{\"question\":\"How was the treatment planned and delivered?\",\"answer\":\"Patients underwent respiratory-gated proton beam therapy using 4D-CT planning, with 20–38 fractions and a prescribed dose of 48–83.6 relative biological effectiveness.\"},{\"question\":\"What outcomes were reported for survival and local control?\",\"answer\":\"The median survival time was 28 months, with 2-year overall survival 51%, progression-free survival 26%, and local tumor control 73%.\"}]","Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers | PDF",1790045234,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2cc821eb9a436bdb1d698d0c405bb7e3.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf37bc2664deca6d6653f2bf8823b7ec.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a90422ad4fb1f15862dda99b22df853.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/549f4bc7f1ce309cabeaec11bc3a9bc0.webp",980,1301]